Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Systemic Juvenile Idiopathic Arthritis Clinical Trial

Official title:
A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

Status Completed

Clinical Trial Summary

This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Arthritis
Arthritis, Juvenile
Systemic Juvenile Idiopathic Arthritis

Clinical Trial Details

NCT number	NCT01803321
Study type	Interventional
Source	Regeneron Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	November 2005
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00891046` - An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.	Phase 3
Completed	`NCT01304420` - Ultrasonography in Juvenile Idiopathic Arthritis	Phase 0
Completed	`NCT02334748` - A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies	Phase 3
Completed	`NCT00144664` - Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)	Phase 3
Completed	`NCT02396212` - Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA	Phase 3
Completed	`NCT00144599` - Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	Phase 3
Terminated	`NCT00886769` - Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)	Phase 3
Completed	`NCT00144612` - Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)	Phase 3
Withdrawn	`NCT01676948` - An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)	Phase 3
Recruiting	`NCT04088396` - A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA	Phase 3
Recruiting	`NCT05027373` - Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection	Phase 1